|
Patient Indication
Please see Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.
|
92 % |
|
ULTOMIRIS (ravulizumab-cwvz) | Official Patient Website
ULTOMIRIS treats adult NMOSD and gMG, and adult and pediatric aHUS and PNH. Please see Important Safety Information and full Prescribing Information, includi...
|
80 % |
|
ULTOMIRIS® (ravulizumab-cwvz) | Official HCP Website
Learn about ULTOMIRIS, a treatment for gMG, aHUS, PNH, and NMOSD. Please see ISI and full PI, including Boxed WARNING.
|
79 % |
|
ULTOMIRIS and SOLIRIS REMS
The goal of the ULTOMIRIS and SOLIRIS REMS is to mitigate the risk of serious meningococcal infections caused by (Neisseria meningitidis serogroups A, C, W,...
|
78 % |
|
ZENBEXUS™ (iberdomide) | For HCPs
Discover ZENBEXUS (iberdomide), the first approved CELMoD agent, for adult patients with relapsed/refractory multiple myeloma. See Safety Info and Full Presc...
|
77 % |
|
Home Page
Home Page
|
76 % |
|
ADCETRIS® (brentuximab vedotin) | Official HCP Website
Discover ADCETRIS® (brentuximab vedotin), a CD30-directed treatment for certain lymphomas. See full Prescribing Information, including BOXED WARNING.
|
76 % |
|
TIBSOVO® (ivosidenib tablets) | mIDH1 Inhibitor
TIBSOVO® is designed to treat some patients with myelodysplastic syndromes, acute myeloid leukemia, & cholangiocarcinoma. See Full Indications & Prescribing...
|
76 % |
|
Home FABHALTA® (iptacopan)
Access information about FABHALTA® (iptacopan) for Health Care Professionals. See full Prescribing and Safety Information, including BOXED WARNING.
|
76 % |
|
BILDYOS® (denosumab-NXXP) injection, for intravenous use | Health Care Providers
Find out more about the BILDYOS® (denosumab-NXXP) injection, for intravenous use.
|
76 % |
|
Home | ProvayBlue
American Regent ProvayBlue
|
75 % |
|
Copiktra REMS
|
75 % |
|
Stemline ARC® | Home Page
Stemline ARC® provides access support, reimbursement assistance, and educational resources so patients can focus on what matters most—their health.
|
75 % |
|
Soliris® (eculizumab) Home | Infusion Center
Soliris® (eculizumab) Infusion Center. Please see Important Safety Information and full Prescribing Information, including Boxed Warning, and Medication Guide.
|
75 % |
|
HaystackAnalytics: Leader in Infectious Genomics
Based out of IIT Bombay, HaystackAnalytics is a HealthTech company creating clinical genomics products, which enable diagnostic labs and hospitals to offer a...
|
75 % |
|
Calvrix ® (calvriumab)
Redefining Control in Rare Vasculitis — The first anti-IL-5 monoclonal antibody indicated for adult patients with moderate-to-severe Eosinophilic Granulomato...
|
75 % |
|
How to order PROLEUKIN® (aldesleukin) Recombinant IL-2
|
74 % |
|
Official Physician Home page | TYSABRI® (natalizumab) HCP
Learn about TYSABRI®. Find HCP resources here, including insights from peers, infusion site locator, and more. See full ISI & Boxed Warning.
|
74 % |
|
Thyroid Hormone Replacement Therapy - SYNTHROID®
Learn about keeping thyroid levels in line with SYNTHROID®, a once daily thyroid hormone replacement therapy for the treatment of hypothyroidism.
|
74 % |
|
ZEPOSIA® (ozanimod) for MS | For HCPs
Discover more about ZEPOSIA® - an oral therapy for your patients with relapsing forms of MS. See full safety and Prescribing Information.
|
74 % |
Detected social media networks